Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025
Stock-based compensation outflow shrinks to $0
Q4 FY2025 stock-based compensation was $0, compared with $87K a year earlier.
Context
- Stock-based compensation increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 2.4M | -25.9% |
| FY2023 | 2023-12-31 | 3.24M | — |
Stock-Based Compensation vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's FY2025 stock-based compensation of $0 is the smallest of the 8 companies compared; the peer median is $5.66M.
- Its year-over-year change of -100.0% is the lowest of 6, against a peer median of +19.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.81M | +19.3% | — | 115500.0% | |
| LTM Mar 2026 | $16.18M | +309.7% | +51.1% | 136.2% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
| LTM Mar 2026 | $5.66M | -29.3% | +12.5% | — | |
| LTM Mar 2026 | $4.3M | — | — | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $638K | — | — | — |
| LTM Mar 2026 | $413.49K | -79.2% | — | 1.5% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | FY2025 | $0 | -100.0% | — | — |
| Peer median (excluding PLYX) | $5.66M | +19.3% | +31.8% | 81.1% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Depreciation & Amortization | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 3.24M | 2.4M | 0 |
| Change in Working Capital | 369K | (621K) | 316K |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | (52K) | (401K) | 398K |
| Other Working Capital | 421K | (220K) | (82K) |
| Other Non-Cash Items | 0 | 26M | 4.73M |
| Operating Cash Flow | (173K) | (2.57M) | (3.94M) |
| Capital Expenditures | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 |
| Debt Repayment | 128K | (128K) | 0 |
| Common Stock Issued | 0 | 7.32M | 4.47M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 |
| Financing Cash Flow | 128K | 7.19M | 4.47M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (45K) | 4.62M | 522K |
| Free Cash Flow | (173K) | (2.57M) | (3.94M) |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.